Patel A, et al. - Within-trial, cost-effectiveness and cost-utility analyses from health and social care (H&SC) and 2 societal perspectives, authors estimated 205 cases to examine the cost-effectiveness of intensive combinations of synthetic disease-modifying drugs (cDMARDS) vs tumor necrosis factor inhibitors (TNFis) in active rheumatoid arthritis. They evaluated the relevant cost and outcome data for 93% of individuals at 6-month follow-up and 91-92% at 12-month follow-up. They noted significantly lower total costs of cDMARDs arm from all perspectives (6-month H&SC adjusted mean difference -£3615; 12-month H&SC adjusted mean difference -£1930). They observed that the HAQ determined the benefit to the cDMARDs arm at 12 months with no differences in other outcomes or follow-ups.